Changes in the utilization of venlafaxine after the introduction of generics in Sweden (Q44560607)

4 December 2017

Changes in the utilization of venlafaxine after the introduction of generics in Sweden (English)

1 reference

4 December 2017

1 reference

7

1 reference

4 December 2017

5

Björn Wettermark

1 reference

4 December 2017

1

Brian Godman

1 reference

4 December 2017

Marie Persson

2

1 reference

4 December 2017

Jamilette Miranda

series ordinal

3

1 reference

4 December 2017

Peter Skiöld

series ordinal

4

1 reference

4 December 2017

Corrado Barbui

series ordinal

6

1 reference

4 December 2017

1 August 2013

1 reference

Applied Health Economics and Health Policy

4 December 2017

1 reference

4 December 2017

11

1 reference

4 December 2017

383-393

1 reference

4 December 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s40258-013-0037-x

4 December 2017

0 references

cites work

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Initiatives to improve prescribing efficiency for drugs to treat Parkinson's disease in Croatia: influence and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Potential savings without compromising the quality of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Acute and continuation treatment adequacy with venlafaxine extended release compared with fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Antidepressants are not all created equal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Different versions of the anatomical therapeutic chemical classification system and the defined daily dose--are drug utilisation data comparable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Interpreting the results of observational research: chance is not such a fine thing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Enhancing the rational use of new medicines across European health care systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

Agomelatine and the brave old world of narrative-based medicine: Table 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0037-X

10.1007/S40258-013-0037-X

21 January 2018

Identifiers

DOI

1 reference

release_lpxuua4uhrbtpayl762wxa3qui

4 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lpxuua4uhrbtpayl762wxa3qui

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference